LCAR-M23

N/A

Report date: 2024/11/07 13:31:38

Base Information

Drug NameLCAR-M23

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionMesothelin inhibitors

TargetsMesothelin

Therapy Area/IndicationsCarcinoma, Ovarian Epithelial

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaDiscontinued

Originator CompaniesNanjing Legend Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNanjing Legend Biotechnology Co Ltd

Active IndicationsN/A

Inactive IndicationsCarcinoma, Ovarian Epithelial

Other Information

ATC CodeN/A